Extracorporeal Cation‐exchange Circuits in the Treatment of Hyperammonæmia of Hepatic Failure

Js, Juggi

doi:10.5694/j.1326-5377.1973.tb110802.x

“…Hemoperfusion consisted in making blood pass through columns containing the resins or the activated charcoal [19][20][21][22][23] for the elimination of water-soluble molecules and lipophilic substances associated with metabolic encephalopathy [24][25][26]. Controlled study showed the absence of improvement of the results by using the hemoperfusion on charcoal column compared to the standard medical treatment [27,28].…”

Section: Hemoperfusion and Plasma-perfusionmentioning

confidence: 99%

Methods of Extracorporeal Liver Support For Treatment of Liver Cell Failure

Adham

¹

2001

Z Gastroenterol

4

0

View full text Add to dashboard Cite

“…24,37 Thus, several approaches to treat renal insufficiency have been proposed. 4,13,15,16,23,29,30,[38][39][40] Some researchers suggest the use of microencapsulated urease to convert urea into ammonia that is subsequently removed by coencapsulated ammonia adsorbent 9,14 or as mentioned above, some researchers propose administering microencapsulated multienzyme complex to convert urea and ammonia into essential amino acids 9,15,39,28 or using lyophilized urea-utilizing soil bacteria. 41,42 Microencapsulated cells have also been reported to be successful in other medical complications.…”

mentioning

confidence: 99%

Potentials and limitations of microorganisms as renal failure biotherapeutics

Prakash¹

2009

BTT

0

View full text Add to dashboard Cite

Renal insufficiency leads to uremia, a complicated syndrome. It thus becomes vital to reduce waste metabolites and regulate water and electrolytes in kidney failure. The most common treatment of this disease is either dialysis or transplantation. Although these treatments are very effective, they are extremely costly. Recently artificial cells, microencapsulated live bacterial cells, and other cells have been studied to manage renal failure metabolic wastes. The procedure for microencapsulation of biologically active material is well documented and offers many biomedical applications. Microencapsulated bacteria have been documented to efficiently remove urea and several uremic markers such as ammonia, creatinine, uric acid, phosphate, potassium, magnesium, sodium, and chloride. These bacteria also have further potential as biotherapeutic agents because they can be engineered to remove selected unwanted waste. This application has enormous potential for removal of waste metabolites and electrolytes in renal failure as well as other diseases such as liver failure, phenylketonuria, and Crohn's disease, to name a few. This paper discusses the various options available to date to manage renal failure metabolites and focuses on the potential of using encapsulated live cells as biotherapeutic agents to control renal failure waste metabolites and electrolytes.

show abstract

“…24,37 Thus, several approaches to treat renal insufficiency have been proposed. 4,13,15,16,23,29,30,[38][39][40] Some researchers suggest the use of microencapsulated urease to convert urea into ammonia that is subsequently removed by coencapsulated ammonia adsorbent 9,14 or as mentioned above, some researchers propose administering microencapsulated multienzyme complex to convert urea and ammonia into essential amino acids 9,15,39,28 or using lyophilized urea-utilizing soil bacteria. 41,42 Microencapsulated cells have also been reported to be successful in other medical complications.…”

mentioning

confidence: 99%

Potentials and limitations of microorganisms as renal failure biotherapeutics

Prakash¹

2009

BTT

2

0

View full text Add to dashboard Cite

Renal insufficiency leads to uremia, a complicated syndrome. It thus becomes vital to reduce waste metabolites and regulate water and electrolytes in kidney failure. The most common treatment of this disease is either dialysis or transplantation. Although these treatments are very effective, they are extremely costly. Recently artificial cells, microencapsulated live bacterial cells, and other cells have been studied to manage renal failure metabolic wastes. The procedure for microencapsulation of biologically active material is well documented and offers many biomedical applications. Microencapsulated bacteria have been documented to efficiently remove urea and several uremic markers such as ammonia, creatinine, uric acid, phosphate, potassium, magnesium, sodium, and chloride. These bacteria also have further potential as biotherapeutic agents because they can be engineered to remove selected unwanted waste. This application has enormous potential for removal of waste metabolites and electrolytes in renal failure as well as other diseases such as liver failure, phenylketonuria, and Crohn's disease, to name a few. This paper discusses the various options available to date to manage renal failure metabolites and focuses on the potential of using encapsulated live cells as biotherapeutic agents to control renal failure waste metabolites and electrolytes.

show abstract

Extracorporeal Cation‐exchange Circuits in the Treatment of Hyperammonæmia of Hepatic Failure

Cited by 23 publications

References 14 publications

Methods of Extracorporeal Liver Support For Treatment of Liver Cell Failure

Methods of Extracorporeal Liver Support For Treatment of Liver Cell Failure

Potentials and limitations of microorganisms as renal failure biotherapeutics

Potentials and limitations of microorganisms as renal failure biotherapeutics

Contact Info

Product

Resources

About